Luca Giacomelli

Luca Giacomelli

Auto-generated profile, based on publicly available information

Luca Giacomelli

Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2008 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
Antonio BaroneAntonio Barone
Antonio Barone
SSStefano Santini
Stefano Santini
SMSimone Marconcini
Simone Marconcini
LGLuca Giacomelli
Luca Giacomelli
GEGherlone Felice Enrico
Gherlone Felice Enrico
UCUgo Covani
Ugo Covani

1 August 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SPSara Pusceddu
Sara Pusceddu
CVClaudio Vernieri
Claudio Vernieri
MMMassimo Di Maio
Massimo Di Maio
RMRiccardo Marconcini
Riccardo Marconcini
FSFrancesca Spada
Francesca Spada
FBF. De Braud
F. De Braud
Metformin seems to have anticancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic neuroendocrine tumors (pNETs). We investigated the association between glycemia and progression-free survival (PFS) of patients with pNETs treated with everolimus and/or somatostatin analogues, as well as the association between metformin use and PFS time. We performed a retrospective analysis of 445 patients with advanced pNET treated at 24 medical centers in Italy from 1999 through 2015. Data on levels of glycemia were collected at time of diagnosis of pNET, before treatment initiation, and during treatment with everolimus (with or without somatostatin analogues), octreotide, or lanreotide. Diabetes was defined as prior or current use of glycemia control medication and/or fasting plasma glucose level ≥ 126 mg/dL, hemoglobin A1c ≥ 6.5% (48 mmol/L), or a random sample of plasma glucose ≥ 200 mg/dL (11.1 mmol/L), with reported classic symptoms of hyperglycemia or hyperglycemic crisis. Patients were assigned to groups based on diagnosis of diabetes before or during antitumor therapy. PFS was compared between patients with vs without diabetes. Among patients with diabetes, the association between metformin use and PFS was assessed. We performed sensitivity and landmark analyses to exclude patients who developed diabetes while receiving cancer treatment and to exclude a potential immortal time bias related to metformin intake. PFS was significantly longer in patients with diabetes (median, 32.0 months) than without diabetes (median, 15.1 months) (hazard ratio for patients with vs without diabetes, 0.63; 95% confidence interval, 0.50–0.80; P = .0002). PFS of patients treated with metformin was significantly longer (median PFS, 44.2 months) than for patients without diabetes (hazard ratio for survival of patients with diabetes receiving metformin vs without diabetes, 0.45; 95% confidence interval, 0.32–0.62; P < .00001) and longer than for patients with diabetes receiving other treatments (median PFS, 20.8 months; hazard ratio, 0.49; 95% confidence interval, 0.34–0.69; P < .0001). In multivariable analysis, adjusted for other factors associated with outcomes, metformin was associated with longer PFS but level of glycemia was not. Metformin was associated with increased PFS of patients receiving somatostatin analogues and in those receiving everolimus, with or without somatostatin analogues. Sensitivity and landmark analyses produced similar results. In a retrospective study of patients with pNETs, we found a significant association between metformin use and longer PFS.

1 February 2010 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
Antonio BaroneAntonio Barone
Antonio Barone
SMSimone Marconcini
Simone Marconcini
LGLuca Giacomelli
Luca Giacomelli
LRLorena Rispoli
Lorena Rispoli
Jose Luis Calvo GuiradoJose Luis Calvo Guirado
Jose Luis Calvo Guirado
UCUgo Covani
Ugo Covani

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Rodolfo SaccoRodolfo Sacco
Rodolfo Sacco
VMValeria Mismas
Valeria Mismas
SMSara Marceglia
Sara Marceglia
ARAntonio Romano
Antonio Romano
LGLuca Giacomelli
Luca Giacomelli
IBIrene Bargellini
Irene Bargellini
In the last decade trans-arterial radioembolization has given promising results in the treatment of patients with intermediate or advanced stage hepatocellular carcinoma (HCC), both in terms of disease control and tolerability profile. This technique consists of the selective intra-arterial administration of microspheres loaded with a radioactive compound (usually Yttrium90), and exerts its therapeutic effect through the radiation carried by these microspheres. A careful and meticulous selection of patients is crucial before performing the radioembolization to correctly perform the procedure and reduce the incidence of complications. Radioembolization is a technically complex and expensive technique, which has only recently entered clinical practice and is supported by scant results from phase III clinical trials. Nevertheless, it may represent a valid alternative to transarterial chemoembolization (TACE) in the treatment of intermediate-stage HCC patients, as shown by a comparative retrospective assessment that reported a longer time to progression, but not of overall survival, and a more favorable safety profile for radioembolization. In addition, this treatment has reported a higher percentage of tumor shrinkage, if compared to TACE, for pre-transplant downsizing and it represents a promising therapeutic option in patients with large extent of disease and insufficient residual liver volume who are not immediately eligible for surgery. Radioembolization might also be a suitable companion to sorafenib in advanced HCC or it can be used as a potential alternative to this treatment in patients who are not responding or do not tolerate sorafenib.

12 October 2010 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
Marco SalernoMarco Salerno
Marco Salerno
LGLuca Giacomelli
Luca Giacomelli
GDGiacomo Derchi
Giacomo Derchi
Niranjan PatraNiranjan Patra
Niranjan Patra
ADAlberto Diaspro
Alberto Diaspro
Surface roughness is the main factor determining bacterial adhesion, biofilm growth and plaque formation on the dental surfaces in vivo. Air-polishing of dental surfaces removes biofilm but can also damage the surface by increasing its roughness. The purpose of this study was to investigate the surface damage of different conditions of air-polishing performed in vitro on a recently introduced dental restorative composite. Abrasive powders of sodium bicarbonate and glycine, combined at different treatment times (5, 10 and 30 s) and distances (2 and 7 mm), have been tested. The resulting root mean square roughness of the surfaces has been measured by means of atomic force microscopy, and the data have been analyzed statistically to assess the significance. Additionally, a fractal analysis of the samples surfaces has been carried out. The minimum surface roughening was obtained by air-polishing with glycine powder for 5 s, at either of the considered distances, which resulted in a mean roughness of ~300 nm on a 30 × 30 μm2 surface area, whereas in the other cases it was in the range of 400-750 nm. Both untreated surfaces and surfaces treated with the maximum roughening conditions exhibited a fractal character, with comparable dimension in the 2.4-2.7 range, whereas this was not the case for the surfaces treated with the minimum roughening conditions. For the dental practitioner it is of interest to learn that use of glycine in air polishing generates the least surface roughening on the considered restorative material, and thus is expected to provide the lowest rate of bacterial biofilm growth and dental plaque formation. Furthermore, the least roughening behaviour identified has been correlated with the disappearance of the surface fractal character, which could represent an integrative method for screening the air polishing treatment efficacy.

1 October 2008 in Journal of Periodontology
Verified
Journal Article
Closed access
UCUgo Covani
Ugo Covani
SMSimone Marconcini
Simone Marconcini
LGLuca Giacomelli
Luca Giacomelli
VSVictor Sivozhelevov
Victor Sivozhelevov
Antonio BaroneAntonio Barone
Antonio Barone
CNClaudio Nicolini
Claudio Nicolini
Background: Genes involved in different biologic processes form complex interaction networks. However, only a few have a high number of interactions with the other genes in the network. In previous bioinformatics and experimental studies concerning the T lymphocyte cell cycle, these genes were identified and termed “leader genes.” In this work, genes involved in human periodontitis were tentatively identified and ranked according to their number of interactions to obtain a preliminary, broader view of molecular mechanisms of periodontitis and plan targeted experimentation.Methods: Genes were identified with interrelated queries of several databases. The interactions among these genes were mapped and given a significance score. The weighted number of links (weighted sum of scores for every interaction in which the given gene is involved) was calculated for each gene. Genes were clustered according to this parameter. The genes in the highest cluster were termed leader genes.Results: Sixty‐one genes involved or potentially involved in periodontitis were identified. Only five were identified as leader genes, whereas 12 others were ranked in an immediately lower cluster. For 10 of 17 genes there is evidence of involvement in periodontitis; seven new genes that are potentially involved in this disease were identified. The involvement in periodontitis has been completely established for only two leader genes.Conclusions: We applied a validated bioinformatics algorithm to increase our knowledge of molecular mechanisms of periodontitis. Even with the limitations of this ab initio analysis, this theoretical study can suggest ad hoc experimentation targeted on significant genes and, therefore, simpler than mass‐scale molecular genomics. Moreover, the identification of leader genes might suggest new potential risk factors and therapeutic targets.